Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

MediciNova reports subgroup analysis from phase IIb SPRINT-MS study of MN-166 in progressive MS

April 2, 2019

European Commission approves Ajovy for migraine prophylaxis

April 2, 2019

FDA issues complete response letter for midazolam nasal spray

April 2, 2019

Merck & Co. optimizes alpha7 nicotinic receptor PAM for cognitive disorders

April 2, 2019

FDA approves Mavenclad for relapsing-remitting and active secondary progressive MS

April 1, 2019

No pain, emotional gain due to newly identified mutation

April 1, 2019

Merck & Co. presents novel AD-specific tau monoclonal antibody, MAFT-0617

April 1, 2019

MR-35602, a novel triple-activity compound with promising activity in model of AD

April 1, 2019

NB-360 improves memory deficit in mice

April 1, 2019

Antiviral etravirine increases frataxin levels: a potential therapy for Friedreich's ataxia

April 1, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.